ReviewFrontiers in oncology2026
Label-free molecular profiling of cancer using Raman spectroscopy: from fundamentals to clinical applications.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early cancer detection and individualized therapy represent two of the foremost challenges in contemporary oncology. Raman spectroscopy, a rapid and label-free technique based on molecular vibrations, has emerged as a powerful tool with significant potential to address these needs. It offers unique capabilities for early cancer detection, real-time histopathological evaluation, tumor classification, and intraoperative diagnosis. This article reviews the fundamental principles of spontaneous Raman spectroscopy and highlights recent advances in enhanced Raman techniques, including coherent anti-Stokes Raman scattering (CARS) and stimulated Raman scattering (SRS). We examine their applications in diagnosing cancers of the lung, liver, colorectum, gastrointestinal tract, and other solid tumors, with a focus on early cancer detection, real-time histopathological evaluation, and label-free tissue characterization. Furthermore, we explore the use of Raman spectroscopy in studying tumor metabolic profiles and the tumor microenvironment, such as extracellular matrix (ECM) profiling, enabling new insights into metabolic imaging and vibrational phenotyping. The review also addresses key technical and translational challenges in Raman-based cancer diagnosis-including signal enhancement, spectral unmixing, instrument miniaturization, and clinical interpretability. Finally, we outline future directions for developing integrated, multimodal diagnostic platforms that combine vibrational spectroscopy with other optical methods. These advances hold great promise for achieving real-time, precise, and personalized cancer management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.